2nd Interstitial Lung Disease Drug Development Summit

With SSc-ILD on the cusp of regulatory approval following closely behind Pirfenidone’s breakthrough therapy designation to treat uILD earlier this year, and investment pouring across multiple ILD phenotypes, the window of therapeutic opportunity to develop clinically defining drugs to treat interstitial lung disease is well and truly open.

The timely 2nd ILD Summit will siphon critical insights from experts at Pfizer, Genentech, Novartis, Boehringer Ingelheim and Pieris Pharmaceuticals to help you to catalyze a new wave of therapies against Scleroderma, Sarcoidosis, COP, CT-ILDs and more.

With 3 unique days of dedicated scientific content - from discovering how to strategically optimize your approach to treating inflammatory vs fibrotic ILDs to learning how to leverage clinical trials to identify novel outcomes and investigating the transformative power of machine learning for ILD imaging - this is the perfect intensive crash course for experts across your team to get up to speed with the latest ILD developments.

Join 20+ brand new speakers and 150+ drug developers from leading companies online to uncover the secrets behind developing industry defining ILD therapies, tailor the experience to meet your needs and supercharge your ILD drug development approach.